HPV – Oral Cancer News

Throat cancer survivors don’t have to sacrifice ability to swallow and taste

Source: southfloridahospitalnews.com Author: staff Tamarac resident Kenneth Goff was home shaving morning when he felt a small lump on the left side of his neck. “There was no pain, no nothing, but I could feel it by the way the razor moved,” said the 58-year-old father of five and grandfather of eight. “It wasn’t visible at all, but I could feel it right below the jaw line.” After a CT scan at Broward Health Medical Center in August 2020, Goff was diagnosed with HPV-mediated squamous cell carcinoma, a type of throat cancer. This cancer is similar to what actors Michael Douglas and Stanley Tucci have battled. The treatment of HPV-related oropharyngeal squamous cell carcinoma may include surgery, radiation, chemotherapy or combination of the treatments. Ryan H. Sobel, M.D., a head and neck surgical oncologist at Broward Health Medical Center, prescribed radiation to treat Goff’s isolated neck mass. Prior to radiation treatment, Dr. Sobel performed a submandibular, or saliva gland transfer, an intricate surgery only a handful surgeons across the country are skilled at performing. He is currently the only surgeon utilizing this technique in Broward and Palm Beach counties. Dr. Sobel strategically relocated one of Goff’s saliva glands. It was moved about three inches from the right side of his throat to under the chin to place it out of direct range of the damaging effects of radiation. Patients diagnosed with throat cancer face a difficult choice: treat the cancer with radiation and risk losing their ability to swallow and [...]

Oral Cancer Foundation News Team - A2022-02-24T15:03:37-07:00February, 2022|Oral Cancer News|

WVU Medicine Head and Neck Cancer Team works to increase tonsil cancer awareness

Source: wvumedicine.org Author: staff, WVU Medicine News Head and neck surgical oncologists at WVU Medicine, the WVU Cancer Institute, and across the country are seeing increased incidences of tonsil cancer. “The majority of tonsil cancers, nearly 70 percent, are caused by human papilloma virus (HPV),” Meghan Turner, M.D., head and neck surgeon in the WVU Medicine Department of Otolaryngology, said. “In the last 10 years, tonsil cancer caused by HPV has become more common than cervical cancer caused by the same virus.” In most cases of HPV infection, the body fights off the virus like it would the common cold. In other cases, the virus remains in the body, increasing the risk of both tonsil and cervical cancer. Unlike cervical cancer, there is no regular screening for tonsil cancer. Most commonly, tonsil cancer is first diagnosed as a nontender mass in the neck. “Another common presentation for tonsil cancer is actually recurrent or persistent tonsil pain in spite of treatment for a throat infection,” Dr. Turner said. “This happens between the ages of 50 and 60. It may seem like recurrent strep throat, but it is uncommon for people in that age range to develop recurrent strep throat. If you’re having pain that isn’t resolved after a course of antibiotics, you should ask your doctor if it could possibly be something like tonsil cancer.” It is also regularly discovered during routine dental visits, appearing as asymmetrical tonsils. Those who have had their tonsils removed by tonsillectomy are not immune to [...]

Oral Cancer Foundation News Team - A2022-02-05T10:20:45-07:00February, 2022|Oral Cancer News|

Trial underway for novel agent plus immunotherapy for HPV-related head and neck cancer

Source: www.curetoday.com Author: Brielle Benyon Results from a phase 2 clinical trial demonstrated promise for the combination of the novel agent PDS0101 plus Keytruda (pembrolizumab) in treating human papillomavirus (HPV)-associated head and neck cancer. As such, the trial will now progress to full enrollment of 54 patients who have not been previously treated with a checkpoint inhibitor. The trial, VERSATILE-002, involves two groups of HPV16-positive patients with head and neck cancer that is either metastatic or has returned after treatment. One group consists of patients who have no prior treatment with checkpoint inhibition immunotherapy, while the other group is made up of 21 patients whose disease failed checkpoint inhibition — assessment for this group is still ongoing. In the checkpoint inhibitor-naïve group, four or more of the 17 patients achieved an objective response, which was classified by a 30% or more reduction in tumor size. “The achievement of this important milestone in the VERSATILE-002 phase 2 clinical trial strengthens the evidence of our novel Versamune platform’s potential ability to induce high levels of tumor-specific CD8+ killer T-cells that attack the cancer to achieve tumor regression,” commented Dr. Lauren V. Wood, Chief Medical Officer of PDS Biotech, the developer of PFS101, in a statement. “The initial data solidifies our belief that PDS0101’s demonstrated preclinical efficacy when combined with Keytruda has the potential to significantly improve clinical outcomes for patients with advanced HPV16-positive head and neck cancers.” PDS0101 works by inducing large quantities of CD4+ helper and CD8+ killer T cells, a [...]

Oral Cancer Foundation News Team - A2022-02-03T10:51:38-07:00February, 2022|Oral Cancer News|

New MSK radiation approach means fewer side effects for more patients with HPV-related head and neck cancer

Source: www.mskcc.org Author: Memorial Sloan Kettering Cancer Center Robert Rosenfeld thought the lump he felt in his neck in late 2018 was just a symptom of a cold that wouldn’t go away. He visited an ear, nose, and throat specialist who saw nothing upon first examination, but Robert knew something was wrong and asked for a CT scan. The specialist called him with the bad news: It was almost certainly cancer. A biopsy confirmed he had stage 2 cancer at the base of his tongue and 2 nearby lymph nodes. The tumor was positive for the human papillomavirus (HPV). Robert, then a 69-year-old car salesman on Long Island, met with cancer doctors near his hometown of Hauppauge, New York, to learn about treatment options. He realized he faced a tough road: Standard treatment would be 7 weeks of radiation, during which he also would receive 3 rounds of chemotherapy. The standard radiation dose would likely cause mouth sores, difficulty swallowing, dry mouth (from damage to salivary glands), loss of taste, and nausea. Robert wanted a second opinion, and his medical oncologist strongly recommended Memorial Sloan Kettering Cancer Center. When Robert called, he was able to get in to see radiation oncologist C. Jillian Tsai the very next day. “When I met Dr. Tsai, she was amazing,” Robert says. “She told me what I was up against but also that the cancer I had was curable.” There was another major plus: Dr. Tsai was able to offer a significantly reduced radiation [...]

Oral Cancer Foundation News Team - A2022-01-20T12:49:57-07:00January, 2022|Oral Cancer News|

Molecular profiling identifies potential prognostic biomarker for treatment response in HNSCC

Source: www.ajmc.com Author: Matthew Gavidia Human papillomavirus surrogate marker p16 was identified as a potential prognostic biomarker for standard-of-care immune checkpoint blockade therapy response in non-oropharyngeal head and neck squamous cell carcinoma. Real-world overall survival among patients with oropharyngeal squamous cell carcinoma (OPSCC) and non-OP head and neck squamous cell carcinoma (HNSCC) differed significantly based on the presence of the human papillomavirus (HPV) surrogate marker p16, with further implications identified regarding time on treatment with immune checkpoint blockade (ICB) therapies. Findings were published in Cancers. Identified as the sixth most common cancer worldwide with incidence expected to increase by 32% in the next 2 decades, patients with recurrent and/or metastatic HNSCC typically have a poor prognosis. Although diagnosis of HNSCC is typically related to tobacco and alcohol use, incidence of HPV-associated HNSCC has risen substantially, in which those positive for the virus whose HNSCC stems in the oropharynx have exhibited better survival outcomes. Researchers sought to further investigate the association of HPV and/or its surrogate marker p16 with response to standard-of-care ICB therapies in patients with OPSCC and non-oropharyngeal (non-OP) HNSCC. “We also investigated other potential biomarkers and mutations that may predict improved response to ICB in both HPV-positive and -negative patients with HNSCC,” they added. Patients registered in the Caris Life Sciences CODEai database with non-OP HNSCC and OPSCC were recruited and identified by comprehensive molecular profiling to be positive or negative for p16. In total, 2905 HNSCC (OPSCC, n = 948) cases were identified. Of those tested for [...]

Oral Cancer Foundation News Team - A2022-01-07T08:27:03-07:00January, 2022|Oral Cancer News|

The ‘big three’ causes of mouth cancer

Source: www.hippocraticpost.com Author: staff By knowing the causes of mouth cancer, we can take positive steps to reduce our own level of risk, says a leading health charity. The Oral Health Foundation is raising awareness about the causes of mouth cancer, following new research that shows far too many people remain unaware of the main risk factors. The number of people diagnosed with mouth cancer in the UK has doubled in the last 20 years, with tobacco, drinking alcohol to excess and the human papillomavirus, being the considered the most common causes. However, new data shows that awareness into the three big risk factors is as low as 15%. With more than half of all mouth cancer cases linked to lifestyle factors, the charity along with Denplan, part of Simplyhealth, are using November’s Mouth Cancer Action Month to shed light on the biggest risks factors associated with the disease. Tobacco Smoking tobacco increases your risk of developing mouth cancer by up to ten times. This includes smoking cigarettes, pipes or cigars. Around two-in-three mouth cancers are linked to smoking. Dr Nigel Carter, Chief Executive of the Oral Health Foundation says: “Despite the number of smokers continuing to fall, it remains the leading cause of mouth cancer. Our focus must be on providing smokers with the support and information they need in order to kick tobacco for good. It’s never too late to quit and by making this positive step, the health of your mouth and body will see both instant [...]

Oral Cancer Foundation News Team - A2021-12-22T13:06:29-07:00December, 2021|Oral Cancer News|

The HPV Vaccine Prevents Cancer, but Most Kids Don’t Receive It

Source: The New York Times Date: December 13th, 2021 Author: Jane E. Brody Cover image courtesy of The New York Times The human papillomavirus vaccine can prevent six potentially lethal malignancies, but inoculation is meeting with rising resistance from parents. Vaccine hesitancy is hardly limited to shots against Covid-19. Even the HPV vaccine, which can prevent as many as 90 percent of six potentially lethal cancers, is meeting with rising resistance from parents who must give their approval before their adolescent children can receive it. The Food and Drug Administration licensed this lifesaving vaccine in 2006 to protect against sexually transmitted infection by HPV, the human papillomavirus. Most of us will get infected with HPV during our lifetimes, certain strains of which can lead to cancers of the cervix, vagina and vulva in women; cancers of the anus and back-of-the-throat in both women and men; and penile cancer in men. HPV can also cause genital warts. But the vaccine only works if it’s administered before people become infected by the virus. And that often means getting vaccinated before teens and young adults have any form of sexual activity, including oral sex and skin-to-skin contact without penetration. More than half of adolescents ages 15 to 19 report having had oral sex, and one in 10 say they have had anal sex. Unless they are vaccinated, more than 80 percent of women become infected with HPV by age 50. And while most infections clear on their own, enough persist to cause many [...]

Charlotte Parker2021-12-17T11:53:24-07:00December, 2021|Oral Cancer News|

Achieving an 80% HPV vaccination rate could eliminate nearly 1 million cases of male oropharyngeal cancer this century

Source: medicalxpress.com Author: University of Texas Health Science Center at Houston A nationwide effort to adequately vaccinate 8 in 10 adolescents against the human papillomavirus (HPV) could prevent 934,000 cases of virus-associated, male oropharyngeal cancer over this century, reported investigators at The University of Texas Health Science Center at Houston (UTHealth Houston) School of Public Health in The Lancet Regional Health—Americas. At the start of each decade, the Healthy People program of the U.S. Department of Health and Human Services establishes goals to reduce the most significant preventable threats to health, which include an 80% target for the HPV vaccination program. However, in the U.S., just 54% of adolescents and only 21% of young adults were adequately vaccinated as of 2019. To gage the effect of accomplishing an 80% target on male oropharyngeal cancer, the most common cancer caused by HPV, UTHealth Houston researchers created a simulation model to project the development of this cancer over a lifetime and to measure the impact of the HPV vaccination. "Our study is the first to develop and validate a comprehensive mathematical modeling framework of the natural history of oral HPV infection and its progression to oropharyngeal cancer," said Ashish A. Deshmukh, Ph.D., MPH, the study's senior author and an associate professor in the Department of Management, Policy and Community Health and associate director of the Center for Health Services Research at UTHealth School of Public Health. "Achievement of the 80% goal by 2025 and maintaining it could lead to the prevention of [...]

Oral Cancer Foundation News Team - A2021-12-16T08:47:19-07:00December, 2021|Oral Cancer News|

HPV-associated head and neck cancer blood test shows promise as a test to replace tissue biopsy

Date: December 2nd, 2021 Author: Massachusetts Eye and Ear Infirmary Source: MedicalXpress Featured Image Courtesy of Mass Eye and Ear Infirmary: Daniel L. Faden, MD, a head and neck surgical oncologist and investigator in the Mike Toth Head and Neck Cancer Research Center at Mass Eye and Ear, and assistant professor of otolaryngology–head and neck surgery at Harvard Medical School. Credit: Mass Eye and Ear Researchers at Mass Eye and Ear and Mass General Hospital have developed a blood test, or liquid biopsy, for head and neck cancer associated with the human papilloma virus (HPV) that was shown in a new study to be more accurate, faster and cheaper than conventional testing methods. In the study, published December 2 in Clinical Cancer Research, a journal of the American Association for Cancer Research, liquid biopsy was more than 98 percent accurate and obtained a diagnosis 26 days quicker on average than conventional tissue biopsy. The cost of the novel test was 38 percent lower than standard methods. When the researchers combined the liquid biopsy with findings from routine imaging and physical exam to create a fully non-invasive diagnostic approach, diagnostic accuracy remained greater than 95 percent. With HPV-associated head and neck cancer rates on the rise, there is a great need for more accurate, less-invasive, faster and less expensive diagnostic tests, according to authors of the study. "Current diagnostic approaches for HPV-associated head and neck cancers are imperfect and invasive, which means patients often need repeat biopsies to get to [...]

Charlotte Parker2021-12-06T11:31:49-07:00December, 2021|Oral Cancer News|

Liquid biopsy provides accurate, fast Dx of HPV-associated head and neck cancer

Source: www.medpagetoday.com Author: Mike Bassett, Staff Writer, MedPage Today The use of liquid biopsy for the diagnosis of human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) was more accurate, faster, and less expensive than standard tissue-based biopsies, according to a prospective observational study. The sensitivity and specificity of this circulating tumor HPV DNA-based approach were 98.4% and 98.6%, respectively, with positive and negative predictive values of 98.4% and 98.6%, reported Daniel L. Faden, MD, of Massachusetts General Hospital and Harvard Medical School in Boston, and colleagues. The diagnostic accuracy of this non-invasive approach was significantly higher than standard of care (Youden index 0.968 vs 0.707, P<0.0001), they noted in Clinical Cancer Research. In addition, liquid biopsy reduced the time to diagnosis from a median of 41 days to 15 days, and estimated costs associated with this method were about 36% to 38% less than the traditional biopsy approach. "Currently the way we diagnose HPV-associated cancer is either with a needle biopsy of a neck lymph node or a tissue biopsy from the oropharynx -- and these approaches have a couple of different limitations," Faden told MedPage Today. Not only are they invasive and painful for patients, but needle biopsy of a neck lymph node has high failure rates due to a lack of adequate cellular material. "So, patients might have to undergo a repeat biopsy to get the diagnosis we are waiting for," he noted. "That adds time to diagnosis, and we know that time from presentation to [...]

Oral Cancer Foundation News Team - A2021-12-03T05:54:26-07:00December, 2021|Oral Cancer News|